Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening

Takai, Tetsunari; Kanaoka, Shigeru; Yoshida, Kenichi; Hamaya, Yasushi; Ikuma, Mutsuhiro; Miura, Naoyuki; Sugimura, Haruhiko; Kajimura, Masayoshi; Hishida, Akira

doi:10.1158/1055-9965.epi-08-0937

Cited by 54 publications

(45 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these guidelines, the stool DNA test was recommended as a CRC screening method; however, the sensitivity and specificity of the stool DNA test was insufficient compared with fecal occult blood test (16). Several studies have reported an attempt to detect CRC by using reverse transcriptase-PCR in fecal samples (17)(18)(19). However, there is no evidence that the stool RNA test is useful for CRC screening.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

Koga

Yasunaga

Takahashi

et al. 2010

Cancer Prevention Research

191

167

View full text Add to dashboard Cite

To reduce the colorectal cancer (CRC) mortality rate, we have reported several CRC screening methods using colonocytes isolated from feces. Expression analysis of oncogenic microRNA (miRNA) in peripheral blood was recently reported for CRC detection. In the present study, we conducted miRNA expression analysis of exfoliated colonocytes isolated from feces for CRC screening. Two hundred six CRC patients and 134 healthy volunteers were enrolled in the study. miRNA expression of the miR-17-92 cluster, miR-21, and miR-135 in colonocytes isolated from feces as well as frozen tissues was analyzed by quantitative realtime PCR. The expression of the miR-17-92 cluster, miR-21, and miR-135 was significantly higher in CRC tissues compared with normal tissues. The exfoliated colonocytes of 197 CRC patients and 119 healthy volunteers were analyzed because of the presence of sufficient miRNA concentration. miR-21 expression did not differ significantly between CRC patients and healthy volunteers (P = 0.6). The expression of miR-17-92 cluster and miR-135 was significantly higher in CRC patients than in healthy volunteers (P < 0.0001). The overall sensitivity and specificity by using miRNA expression was 74.1% (146/197; 95% confidence interval, 67.4-80.1) and 79.0% (94/119; 95% confidence interval, 70.6-85.9), respectively. Sensitivity was dependent only on tumor location (P = 0.0001). miRNA was relatively well conserved in exfoliated colonocytes from feces both of CRC patients and healthy volunteers. miRNA expression analysis of the isolated colonocytes may be a useful method for CRC screening. Furthermore, oncogenic miRNA highly expressed in CRC should be investigated for CRC screening tests in the future. Cancer Prev Res; 3(11); 1435-42. ©2010 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

Koga

Yasunaga

Takahashi

et al. 2010

Cancer Prevention Research

191

167

View full text Add to dashboard Cite

show abstract

“…Several attempts to use DNA- [22,23] or RNA-based molecular biological methods [24][25][26] for the early detection of CRC have been reported. However, these methods have not proved superior to the FOBT in terms of sensitivity and specificity.…”

Section: Fecal Mirna Test To Detect False Negative Fobt Resultsmentioning

confidence: 99%

MicroRNA analysis of colorectal cancer using fecal and tissue samples

2017

RNA Dis

View full text Add to dashboard Cite

Recently, several microRNAs (miRNAs) have been reported as promising biomarkers for cancer detection and tumor recurrence risk. Due to its stability, miRNA can be accessed from samples stored in severe conditions, such as feces or formalin-fixed paraffin-embedded (FFPE) tissue. Fecal miRNA extracted from the residuum of fecal occult blood tests (FOBTs) was assessed to determine whether a combination of this fecal miRNA test (FmiRT) with FOBT could improve the false-negative rate of colorectal cancer (CRC) screening compared with FOBT alone. Expression of miR-106a in patients with both positive and negative FOBTs was significantly higher than in healthy volunteers. To identify a high-risk group for recurrence, miRNAs were extracted from FFPE samples of patients with stage II CRC. Tumor recurrence occurred at a significantly higher rate in patients with increased miR-181c expression than in those with lower expression. The recurrence rate in patients with stage II CRC with higher expression of miR-181c was similar to that of patients with stage III CRC who had been treated by surgical resection alone. As miRNAs are stable in several severe storage conditions, such as in fecal and FFPE samples, they could be valuable, accessible biomarkers for CRC, for use both in cancer screening and as predictors of recurrence.

show abstract

“…The fecal RNA expression analysis of PTGS2 by semi-quantitative RT-PCR was reported to have sensitivities of 50-90% and specificities of 93-100% in previous studies (22,26,30). Semi-quantitative RT-PCR was used in the majority of previous studies on fecal RNA expression analysis for CRC screening, while real-time RT-PCR was used in only a few studies (29).…”

Section: Discussionmentioning

confidence: 99%

“…Methods using fecal DNA allow for the detection of mutated (13)(14)(15)(16), methylated (17)(18)(19)(20)(21)(22) or long DNA (21,23,24). Results from various studies on fecal RNA-based analysis by reverse-transcription polymerase chain reaction (RT-PCR) for CRC screening have been reported (25)(26)(27)(28)(29)(30)(31). Altered messenger RNA (mRNA) expression of numerous genes has been noted in CRC, but only a few genes have been studied to investigate the usefulness of fecal RNA analysis in CRC detection.…”

Section: Introductionmentioning

confidence: 99%

Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening

Miyamoto¹,

Miyamoto²,

Yamamoto³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. Interferon-induced transmembrane protein (IFITM) is reported to be frequently overexpressed in colorectal tumors. This study aimed to determine the usefulness of detecting fecal IFITM messenger RNA (mRNA) by real-time reverse-transcription polymerase chain reaction (RT-PCR) for colorectal cancer (CRC) screening. This pilot study included 21 patients with CRC and 23 healthy controls. Total RNA was isolated from the feces of the patients, and the expression levels of the mRNA of IFITM1, IFITM2 and IFITM3 were measured by real-time RT-PCR to detect CRC. Receiver operating characteristic curves of respective genes were generated, and the area under the curve (AUC), sensitivity and specificity were determined. When the 44 patients were analyzed, the AUCs of fecal IFITM1, IFITM2 and IFITM3 expression analysis were 0.82, 0.80 and 0.65, respectively. The sensitivities were 67% [14/21; 95% confidence interval (CI) 43-85%], 67% (14/21; 95% CI 43-85%) and 71% (15/21; 95% CI 48-89%), respectively; and the specificities were 96% (1/23; 95% CI 78-100%), 96% (1/23; 95% CI 78-100%) and 61% (9/23; 95% CI 39-80%), respectively. When IFITM1 and IFITM2 were combined, the sensitivity was 86% (18/21; 95% CI 64-97%) and the specificity was 96% (1/23; 95% CI 78-100%). The fecal expression analysis of IFITM1 and IFITM2 mRNA by real-time RT-PCR for CRC screening exhibited high specificities, and the sensitivity was further improved by combining IFITM1 and IFITM2.

show abstract

Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening

Cited by 54 publications

References 42 publications

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

MicroRNA analysis of colorectal cancer using fecal and tissue samples

Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening

Contact Info

Product

Resources

About